{"id":1068069,"date":"2020-10-28T15:27:48","date_gmt":"2020-10-28T19:27:48","guid":{"rendered":"https:\/\/www.immortalitymedicine.tv\/betterlife-provides-important-update-on-its-australian-clinical-study-design\/"},"modified":"2024-08-18T11:42:33","modified_gmt":"2024-08-18T15:42:33","slug":"betterlife-provides-important-update-on-its-australian-clinical-study-design","status":"publish","type":"post","link":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/global-news-feed\/betterlife-provides-important-update-on-its-australian-clinical-study-design.php","title":{"rendered":"BetterLife Provides Important Update on its Australian Clinical Study Design"},"content":{"rendered":"<p><![CDATA[Vancouver, Oct.  28, 2020  (GLOBE NEWSWIRE) -- BetterLife Pharma (OTCQB:BETRF) (CSE:BETR), an emerging biotechnology company preparing human clinical trials of AP-003, its interferon alpha 2b inhalation therapy for the treatment of COVID-19, today provided the following update regarding how it expects to overcome potential challenges of recruiting patients for human trials.]]><\/p>\n<p>View post:<br \/>\n<a target=\"_blank\" rel=\"nofollow noopener noreferrer\" href=\"http:\/\/www.globenewswire.com\/news-release\/2020\/10\/28\/2115892\/0\/en\/BetterLife-Provides-Important-Update-on-its-Australian-Clinical-Study-Design.html?f=22&amp;fvtc=5&amp;fvtv=46634288\" title=\"BetterLife Provides Important Update on its Australian Clinical Study Design\">BetterLife Provides Important Update on its Australian Clinical Study Design<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>View post: BetterLife Provides Important Update on its Australian Clinical Study Design <a href=\"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/global-news-feed\/betterlife-provides-important-update-on-its-australian-clinical-study-design.php\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":64,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"limit_modified_date":"","last_modified_date":"","_lmt_disableupdate":"","_lmt_disable":"","footnotes":""},"categories":[1246886],"tags":[],"class_list":["post-1068069","post","type-post","status-publish","format-standard","hentry","category-global-news-feed"],"modified_by":null,"_links":{"self":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/1068069"}],"collection":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/users\/64"}],"replies":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/comments?post=1068069"}],"version-history":[{"count":0,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/1068069\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/media?parent=1068069"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/categories?post=1068069"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/tags?post=1068069"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}